New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

More documents

Recommendations

Info

2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Rivaroxaban - Xarelto • 9/22/2011 Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban in Europe. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued two "positive opinions" for the oral factor Xa inhibitor: one in the setting of the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation (AF) and one for the treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) Ticagrelor – Brilinta by Astra Zeneca 90 mg tablets Loading dose 180 mg then 90 mg BID $217.20 per month WAC Wayne Weart New Drug Update Part I
2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Ticagrelor - Brilinta • Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. • Transitioning from clopidogrel to ticagrelor resulted in an absolute inhibition of platelet inhibition (IPA) increase of 26.4% and from ticagrelor to clopidogrel resulted in an absolute IPA decrease of 24.5%. Patients can be transitioned from clopidogrel to ticagrelor without interruption of antiplatelet effect Mean inhibition of platelet aggregation (±SE) following single oral doses of placebo, 180 mg ticagrelor, or 600 mg clopidogrel Wayne Weart New Drug Update Part I
Page 1 and 2: 2 nd Annual Essentials in Primary C
Page 39: 2 nd Annual Essentials in Primary C
Page 77: 2 nd Annual Essentials in Primary C

New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

Create successful ePaper yourself

Delete template?

Save as template?